7X2O image
Entry Detail
PDB ID:
7X2O
EMDB ID:
Keywords:
Title:
Cryo-EM structure of Coxsackievirus B1 mature virion in complex with nAb 2E6 (CVB1-M:2E6)
Biological Source:
PDB Version:
Deposition Date:
2022-02-25
Release Date:
2022-09-28
Method Details:
Experimental Method:
Resolution:
3.15 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Virion protein 1
Chain IDs:A
Chain Length:278
Number of Molecules:1
Biological Source:Coxsackievirus B1
Polymer Type:polypeptide(L)
Description:VP2
Chain IDs:B
Chain Length:263
Number of Molecules:1
Biological Source:Coxsackievirus B1
Polymer Type:polypeptide(L)
Description:VP3
Chain IDs:C
Chain Length:238
Number of Molecules:1
Biological Source:Coxsackievirus B1
Polymer Type:polypeptide(L)
Description:Capsid protein VP4
Chain IDs:D
Chain Length:69
Number of Molecules:1
Biological Source:Coxsackievirus B1
Polymer Type:polypeptide(L)
Description:2E6 heavy chain
Chain IDs:F (auth: H)
Chain Length:119
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:2E6 light chain
Chain IDs:E (auth: L)
Chain Length:107
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail.
Cell Host Microbe 30 1279 ? (2022)
PMID: 36002016 DOI: 10.1016/j.chom.2022.08.001

Abstact

Coxsackievirus B1 (CVB1) is an emerging pathogen associated with severe neonatal diseases including aseptic meningitis, myocarditis, and pancreatitis and also with the development of type 1 diabetes. We characterize the binding and therapeutic efficacies of three CVB1-specific neutralizing antibodies (nAbs) identified for their ability to inhibit host receptor engagement. High-resolution cryo-EM structures showed that these antibodies recognize different epitopes but with an overlapping region in the capsid VP2 protein and specifically the highly variable EF loop. Moreover, they perturb capsid-receptor interactions by binding various viral particle forms. Antibody combinations achieve synergetic neutralization via a stepwise capsid transition and virion disruption, indicating dynamic changes in the virion in response to multiple nAbs targeting the receptor-binding site. Furthermore, this three-antibody cocktail protects against lethal challenge in neonatal mice and limits pancreatitis and viral replication in a non-obese diabetic mouse model. These results illustrate the utility of nAbs for rational design of therapeutics against picornaviruses such as CVB.

Legend

Protein

Chemical

Disease

Primary Citation of related structures